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ABSTRACT 
Breast cancer screening (BCS) has been recommended to women by healthcare providers 
as well as professional organizations and non-profit awareness organizations for over four 
decades. Recently, attention is being paid to quantification of the actual benefits and harms of 
BCS with mammography. The harms include overdiagnosis, overtreatment and mandate of 
mammography screening that may not be in alignment with the individual values and 
preferences of women ages 40-69. This evidence translation project developed a resource for 
practice that was evaluated by community participants for alignment with personal value and 
preference-based educational needs about BCS. This project piloted a clinical practice decision 
aid (DA), called My Personal Decision (MPD), directly to a community-based convenience 
sample of women ages 40-69. Through a small sample of women, a change in knowledge about 
the harms and benefits of BCS was demonstrated. Evaluation feedback from the participants 
before and after use of the tool confirmed that MPD was helpful and enhanced preparedness for 
BCS decision-making. Provision of evidence-based information directly to women in the 
community setting was well received and perceived as valuable in the screening decision-making 
process in this context. Understanding of evidence-based information is a fundamental element 
in the empowerment of the decision maker with the goal of informed decision-making.  
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At this time, the cumulative evidence for breast cancer screening (BCS) does not 
demonstrate unquestionable benefits in the improvement of mortality with any particular method. 
There are well-established harms and benefits related to BCS with mammography. Conflict 
among professional screening recommendations provides an opportunity to encourage the 
empowerment of individual women in the BCS decision-making process. The use of decision 
aids (DA) has been clearly demonstrated to be most valuable when individual value and 
preference-based decisions include consideration of evidence-based harms and benefits (Stacey 
et al., 2017). The principle of shared decision-making (SDM) supports engagement and 
individual education using DAs. The HealthyUNH program has aligned their support of the 
SDM process within the context of community education. This provides a unique opportunity to 
develop and evaluate a DA resource that can be shared with women in the community setting to 
improve individual informed decision-making (IDM) about BCS. 
 
Available knowledge 
Background: The History of Breast Cancer Screening. Technical advances in 
screening for breast cancer have increased the early diagnosis and treatment of this potentially 
deadly disease in the United States (US) in the last 50 years. Since the 1970’s, screening for 
early signs of breast cancer have included self-breast exam (SBE) along with clinical breast 
exam (CBE) with or without mammography (Picard, 1998). For SBE, evidence now questions 
the impact of SBE on mortality (Kosters & Gøtzsche, 2003; Thomas et al., 2002). Follow up on 
the lack of evidence to support SBE, brought forth questions on the usefulness of the CBE with 
and without mammography.  
At this time, the cumulative evidence for BCS with any method does not demonstrate 
unquestionable benefits in the improvement of mortality. However, distinct and concerning 
harms have been identified. Therefore, understanding of the nature and magnitude of harms as 
well as benefits is imperative for the informed decision-maker.  
  
5 
BREAST CANCER SCREENING DECISION AID 
The Study of Mammography and Emergence of Harms and Benefits of Screening. 
The first supportive evidence for mammography in BCS was reported by the Health Insurance 
Plan of New York which was conducted from 1963-1986. The study examined the impact of 
CBE with mammography vs control group and reported a 40% relative risk reduction in 
mortality from breast cancer among the intervention group of women over the age of 50 
compared to control. This reduction in mortality was noted to become evident 3-4 years after 
screening with CBE and mammography. However, the authors report: “among women aged 40-
49, the benefits in terms of mortality are less clear.” No benefit was directly evident with 
screening among this 40-49 age group in the HIP trial nor in corroborating studies at that time 
(Shapiro et al., 1988). Further, Shapiro et al. (1988) caution about the potentially harmful impact 
of the false-sense of security women receive from mammography results screening (true negative 
or false-negative) as well as the negative psychological and or physical sequelae from false-
positive results. The psychological and physical burden of follow-up as well as the monetary and 
physical cost incurred to clarify and or diagnose (biopsy) false-positive results are also identified 
as concerns that must be considered. Finally, Shapiro et al. (1988) encourage consideration of 
alternatives to mammography with reservation of its use for diagnosis vs. screening (Shapiro et 
al., 1988).  
 A 25-year cumulative study of BCS in Canada that enrolled participants between 1980 
and 1985, found that there was no reduction in mortality from the use of CBE with 
mammography among women ages 40-59 (Miller et al., 2014). All women received annual CBE. 
Participants were randomized to receive annual mammography from age 40-59 or to the control 
group which provided CBE and usual community care between the ages 40-49 with annual 
mammography from age 50-59. Miller et al. (2014) reported that a total of 3250 women who 
received mammograms, and 3133 from the control group received a diagnosis of breast cancer. 
Subsequently, 500 women (between the ages of 40-59) in the mammography group, and 505 
women in the control group, died of breast cancer (hazard ratio 0.99, [0.88, 1.12]) with CI of 
95%. This demonstrates that there was no difference in mortality between groups of women who 
had CBE with mammography between the ages of 40-49 and women who only had routine 
annual mammography between the ages of 50-59. Miller et al. (2014) also reported that long 
term (15 year) analysis revealed that 106 cases of overdiagnosis of breast cancer were observed 
in the mammography arm.  
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In 1999, Dr. Peter Gøtzsche, Director of The Nordic Cochrane Centre and professor of 
Clinical Research Design and Analysis at the University of Copenhagen, reported on the harms 
of mammography screening in a solicited report to the Swedish parliament. At that time, 
Gøtzsche and his team concluded that the harms and benefits of mammography were 
undetermined. Thus, Gøtzsche successfully deterred the Swedish government from providing 
mammograms in all provinces of that nation. This provided the opportunity for comparisons 
between the twenty provinces where mammography was provided, and the five where it was not 
offered (Gøtzsche, 2015).  In systematic review and meta-analysis, Gøtzsche & Jorgensen (2013) 
demonstrated that deaths ascribed to any cancer were not affected by BCS. In adequately 
randomized controlled trials, 66013 women of all ages had screening and 66105 women of all 
ages did not have screening. The relative risk ratio of death from any cancer was 1.02 [0.95, 
1.10] with CI of 95%. Further, it was aggregated that of 119897 women of all ages who had 
screening, and 173061 women of all ages who did not have screening, relative risk of death from 
breast cancer (M-H fixed, 955 CI) after seven years was 0.93 [0.79,1.09].  Unfortunately, this 
minor theoretical benefit from screening was aggregated to be ten times smaller than the relative 
risk of potential harm from overdiagnosis and overtreatment in systematic review (Gøtzsche & 
Jorgensen, 2013). In analysis, the authors’ observed that for 1000 women of screening age who 
choose to have mammography screening, within 10 years: 100 will receive false-positive results; 
22 will likely die from any cancer; 4 will likely die from breast cancer; and 5 will be 
overdiagnosed and overtreated. For 1000 women of screening age who choose not to have 
mammography screening, within 10 years: 0 will receive false-positive results; 22 will likely die 
from any cancer; 5 will likely die from breast cancer; and 0 will be overdiagnosed and 
overtreated. Yet, these are observations that are not well known to the public.  
The “Malmo” randomized controlled trials (RCTs) in Sweden, on which Gøtzsche bases 
many of his recommendations against “routine” BCS (Gøtzsche, 2015), started in 1976. Women 
across a 25-year cohort (born 1908-1932) were randomized for participation in mammography 
screening or no participation in screening. Report of results in 1988 by Andersson et al., showed 
that at a mean follow-up interval of 8.8 years, 588 cases of breast cancer were diagnosed in 
women of all ages in the mammography group and 447 were diagnosed in the control group. 
Among these women, 99 women in the mammography group vs 94 women in the control group 
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died of breast cancer. This is not a statistically significant difference [relative risk 0.96 [0.68, 
1.35] with CI 95%. However, for women over the age of 55, fewer women who had 
mammography (20% reduction) died of breast cancer than women in the control group (35 vs 44; 
relative risk 0.79 [0.51, 1.24]) (Andersson, et al., 1988). Data is still collected in Sweden from 
this cohort in order to provide long term morbidity and mortality observation (Gøtzsche, 2015). 
The current Malmo trial to compare traditional mammography with breast tomosynthesis 
screening (ClinTrials.gov Identifier NCT01091545), started in 2010 with a new cohort of women 
in Sweden.  
In 2014, Pace & Keating pooled results from existing randomized clinical trials in 
systematic review of the impact of mammography on mortality reduction. The authors observed 
that across all age groups, mammography screening reduced the relative risk of overall mortality 
from breast cancer approximately 19%.  This represented a relative risk reduction of 15% for 
women in their 40’s (448 events/152,300 women in the invited group vs 625 events/195,919 
women in the control group) and 32% (110 events /19,093 women in the invited group vs 155 
events /18,377 women in the control group) reduction for women in their 60’s. Pace & Keating 
(2014) found that among 10,000 50-year-old women who have mammograms every year for 10 
years, approximately 61% will experience a false-positive result. This means that 6,130 women 
(95%CI, 5800-6470) will experience a false-positive (Pace & Keating, 2014).  
Further, woman with risk factors for breast cancer were noted to demonstrate a benefit 
from mammography that was exponentially equivalent to their individual risk. For example, a 
healthy 40-year-old with two-fold increase risk for breast cancer due to increased density in her 
breast tissue has a correspondingly two-fold increase in benefit from annual mammography 
screening. Unfortunately, this also means she has a two-fold increase in risk of false-positive 
results (Pace & Keating, 2014). 
A cohort study in Denmark, Jorgensen et al. (2017) found that “it is likely that 1 in every 
3 invasive tumors and cases of DCIS diagnosed in women offered screening represent 
overdiagnosis”. Support of these findings is Loberg’s review that found that 200 women in 1000 
received a false positive result from mammography and 30 women in 1000 received a false 
positive result after biopsy. In this review, 2 women in 1000 were correctly identified with breast 
cancer and subsequently appropriately treated (Loberg et al., 2015).  
Recognizing that BCS demonstrated a small amount of absolute risk and relative risk 
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reduction in mortality related to breast cancer, much attention has been turned to quantification of 
the harms and benefits related to false positive and or false negative results. The implications of 
overdiagnosis and overtreatment has been evaluated by many authors in the last decade (Marmot 
et al., 2013; Welch et al., 2009; Welch et al., 2016).   
Based on the summary of the evidence, Dr. Gøtzsche asserts that the decline in mortality 
from breast cancer is primarily due to improved awareness and treatment unrelated to screening 
behaviors (Gøtzsche, 2013; Gøtzsche, 2015). Gøtzsche further asserts: “my conclusion is that 
screening should be stopped because it is harmful. Also, because a quarter of women screened 
will get a false-positive result. In the US it is double because you are more aggressive here in the 
US. Screening causes overdiagnosis and kills healthy women. We must stop this.” 
These harms and benefits of BCS, have encouraged health care providers as well as some 
community members to seek guidance about screening behaviors. Concurrently, professional 
health care organizations have become more and more active in the production of 
recommendation guidelines for the onset and frequency of screening behaviors. Professional 
organizational guidelines are utilized to direct the behavior of healthcare providers and women 
throughout the United States (US). As such, it is important to understand which guidelines are 
based on high quality evidence and how women can best become aware of recommendations and 
consider incorporation of them in IDM about screening behaviors.  
Professional Organization Recommendation Guidelines. With growing scientific 
information about the harms of BCS, task forces, review groups and expert panel discussions 
were established to review the evidence and recommend best practice guidelines for BCS 
activities. Consequently, several professional health care organizations have come forward with 
BCS recommendation guidelines to influence the manner and frequency of screening for women 
of varying age groups. These organizations include the American Cancer Society (ACS), the 
United States Preventative Services Task Force (USPSTF) and the American Congress of 
Obstetricians and Gynecologists (ACOG). Many other professional organizations have released 
guidelines as well including, the National and Comprehensive Cancer Network (NCCN), the 
American College of Radiology (ACR) and the Society of Breast Imaging (SBI). A summary of 
current recommendation guidelines can be viewed in Table 1. The historical development of 
guidelines by three of these professional health care organizations, ACS, USPSTF and ACOG is 
presented in the following text. 
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The American Cancer Society (ACS). Initial BCS guidelines from the ACS emerged 
after the HIP trial started in New York in 1963. The purpose of the HIP trial was to study the 
effects of as a mammography as a screening tool for breast cancer, on the mortality of women 
(Lerner, 2003). Mammography was developed in the early 1900’s as a diagnostic tool for breast 
cancer. Although not well received until the 1960’s the use of mammography for diagnosis was 
embraced in the mid-1960’s (Houssami & Miglioretti, 2016).  
At that time, the ACS published recommendations that directed women to begin SBE in 
the teen years and consider mammography at the age of 35 if they have a personal history of 
breast cancer. At that time, the ACS further recommended that women between the ages of 40 
and 49, with a first-degree relative with breast cancer, should undergo mammography while all 
Table 1.  
Breast Cancer Screening Recommendation Guidelines (alphabetical order)  
for women at average risk 
 












of “Breast Self- 
Awareness” 
None Age 25-40 
years:  
every 1-3 years 






























Age > 40 
years:  Annual 








Age > 55 years: 
Biennial 
(as long as 
overall health 
is good with 
life expectancy 
> 10 years) 
Age 50-74 
years: Biennial 










after age 55) 
As above As above 
Source ACS, 2016 Siu, 2016 ACOG, 2017 ACR, 2016 NCCN, 2017 
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women should consider annual mammograms starting at the age of 50 (ACS History, 2017).  
 In 1983, the ACS changed their original recommendation and released guidelines that 
encouraged women 20 and over to perform SBE monthly, have CBE every three years and begin 
annual CBE at the age of 40. Mammography was recommended for baseline at age 35 with 
annual – biennial mammography between ages 40 and 49. Annual mammograms were 
recommended beginning at age 50. In 1997 annual mammography recommendation was moved 
to age 40 and remains at that interval until 2015 (ACS History, 2017).  
The 2015 guideline update from the ACS (Oeffinger et al., 2015) increased the 
recommended age of initiation of annual mammography screening, for women who are of 
average risk for the development of breast cancer in their lifetime, from 40 (Oeffinger et al., 
2015) to 45 to 54 with biennial mammography recommended to begin at the age of 55. This was 
upheld by the ACS in 2016 (ACS, 2016).  
The United States Preventative Services Task Force (USPSTF). In 1984 the USPSTF 
established an expert panel that was chartered by legislation to review scientific evidence and 
provide recommendations to clinical experts, clinicians and the public about preventative 
healthcare (USPSTF, 2002). The USPSTF is prohibited by law from consideration of cost 
effectiveness in screening program recommendations (AHRQ, 2017). By end of the 20th century, 
the Mammography Quality Standards Act (MQSA) was established in the US and lower doses of 
radiation per exam and standardization of reporting were mandated (US Food & Drug Admin, 
2017). In 1997, an NIH Consensus Conference concluded “the data currently available do not 
warrant a universal recommendation for mammography for all women in their forties. Each 
woman should decide for herself whether to undergo mammography” (NIH, 1997). Despite this, 
the US Senate subsequently voted 98-0 in favor of provision of BCS for women in their 40’s.  
Subsequently, a windfall of data was published in the medical literature and the USPSTF 
reviewed and updated their recommendation in 2002 to state that women in their 40’s should 
have mammography screening every 2 years (USPSTF, 2002).   
In 2009, the USPSTF updated their guidelines to remove routine recommendations for 
average risk women before the age of 50 stating “The decision to start regular, biennial screening 
mammography before the age of 50 years should be an individual one and take patient context 
into account, including the patient's values regarding specific benefits and harms.” In an 
unprecedented recommendation, biennial mammography for women 50-74 years was 
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recommended. Insufficiency of evidence to assess the benefits and harms of screening 
mammography in women 75 years and older was also reported in the 2009 USPSTF guideline 
(USPSTF, 2009). 
In 2016, after systematic review and meta-analysis of the harms and benefits of BCS, the 
USPSTF released guidelines that enunciated the recommendations under which women under 
the age of 40 should undergo CBE with or without mammography. It was in this detailed 
guideline that concern about overdiagnosis, overtreatment and false-positive results was 
delineated for average risk women between 40 and 49 years of age. However, the need for 
individual preference-based decision-making about beginning mammography before age 50 was 
also advised (Siu, 2016).  
The ACS published criticism of the USPSTF stating women should be guided to begin 
annual mammography at the age of 40 (ACR & SBI, 2016). Debra Monticciolo, MD of the ACR 
stated “following these USPSTF recommendations would result in lethal consequences for 
thousands of women each year.” The ACR and SBI further contended that reports of 
overdiagnosis are “vastly inflated” as they include ductal carcinoma in situ (DCIS). And they 
state “few, if any, invasive cancers are over-diagnosed” (ACR & SBI, 2016).  
The American Congress of Obstetricians and Gynecologists (ACOG). Based on public, 
clinical and academic debate, along with the recognized lack of corroborating recommendations, 
ACOG convened a “multidisciplinary forum” in January 2016 “to address the need for harmony 
among recommendations.” An extensive statement, that outlined the key points for IDM was 
published in May 2016. In June of 2017, ACOG released an update to prior recommendations 
that emphasized early recognition of and intervention for breast cancer. Breast cancer is 
recognized by ACOG as the second leading cause of cancer death among US women. While 
regular screening mammography starting at age 40 is credited with reducing breast cancer 
mortality in average-risk women, the potential harms of screening such as “false-positive test 
results and overdiagnosis of biologically indolent lesions” (ACOG, 2017). However, while 
continuing to underline the value of screening mammography and its role in reduction of 
mortality related to breast cancer, the recommendation for shared decision-making across the 
lifespan was underscored in this updated guideline.  According to ACOG, women’s health-care 
providers should provide the opportunity for women between the ages of 40-75, who are at 
average risk for breast cancer, to engage in shared decision-making that includes discussion 
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about benefits and harms of mammography every 1-2 years. Further, ACOG (2017) guidelines 
recommend that women are encouraged to have a mammogram by the age of 50 with subsequent 
shared decision-making opportunities, to address the frequency of ongoing screening every 1-2 
years until the age of 75.   
In the context of these complicated and conflicting recommendations about the benefits 
as well as harms of BCS, there are many challenges to IDM for women who are between the 
ages of 40 and 75 and are determined to be at average-risk for breast cancer.  
 
Rationale 
Informed Decision-making. The process of IDM involves the use of evidence to guide 
decisions on the part of an individual. The decision to undergo BCS provides medically 
reasonable alternatives based on the value of the harms and benefits implicit in the applied 
technology, in this case, mammography. IDM in this context supports the acquisition of 
preemptive knowledge of these harms and benefits.  
The principle of SDM replies upon the incorporation of IDM in a process that is shared 
between the patient and the provider. SDM is the process of sharing information between a 
healthcare provider and patient, when there are options or choices that have unique benefits and 
harms. The provider shares evidence-based information about the benefits and harms of the 
choices available, and the patient weighs this in light of their own values and preferences, to 
ultimately make the decision at hand. SDM has been demonstrated to improve healthcare and 
reduce costs (O’Connor et al., 2004).  
Reports about the harms and benefits of BCS in the medical literature, media and in 
printed pamphlets are subject to (among other things), the influence of selective reporting, 
commercial influence, defensive practice, statistical illiteracy and over-estimation of treatment 
benefits. Further, time constraints on provider-patient consultations can limit interactions and 
prevent effective information sharing. HCPs are noted to report relative risk reduction more 
frequently than the more objective report of absolute risk reduction as advocated by established 
best practice. Importantly, provision of information to patients outside of the clinical encounter is 
noted to improve the balance of the provider-patient relationship and enhance preparedness for 
the counseling discussion (Bodemer & Gaissmaier, 2012).  
Based on these variables, the decision to undergo mammography screening among 
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women aged 40-49 is recommended by ACOG and the USPSTF to take place in the context of 
IDM. The resultant shared decision between the provider and female patient should be based on 
the individual values and preferences of the individual as informed by the existing medical 
evidence. Based on the prior evidence related to screening by Gøtzsche & Jorgensen (2013) as 
well as the high level of evidence by the USPSTF recommendations (Siu, 2016) and ACOG’s 
(2017) emphasis on shared decision-making across the life span, it is clear there is a need for 
informed decision-making about BCS by women between the ages of 40-75. For the purposes of 
this project, women between the ages of 40-69 were targeted to receive the DA and provide 
feedback. This population of women are able to utilize the information for a minimum of 5 years 
into the future and thus provide value-based responses about helpfulness and preparedness in 
decision-making.  
Breast Cancer Screening as a Preference-Sensitive Care Decision and Decision Aids.  
When there is more than one acceptable option for screening, diagnosis and or treatment 
in healthcare, the decision-making process is considered to be preference-sensitive, i.e. based on 
the preference of the patient. Decisions that involve “tradeoff’s affecting the patient’s quality 
and/or length of life” (Dartmouth Atlas, 2007) should reflect the values and preferences of the 
patient and family. In a systematic assessment of benefits and harms to guide BCS decisions, 
Pace & Keating. (2014) asserted that individualized screening decisions based on the perception 
of individual risk and value-based preferences are important for effective and satisfactory 
healthcare. 
It is asserted that the US healthcare system suffers from “unwarranted variation” due to 
the underuse of effective care, the misuse of preference-sensitive care and the overuse of supply-
sensitive care (Dartmouth Atlas, 2007). In healthcare, the misuse of preference-sensitive care 
occurs when the harms and benefits of a screening and or treatment decision are not effectively 
communicated and therefore, the choice made is not based on the values of preferences of the 
patient (Dartmouth Atlas, 2007). To avoid this unwarranted variation, the use of SDM and DAs 
in BCS has been validated by evidence-based medicine for more than a decade (Gunn, 2015; 
O’Connor et al., 2004). DA’s are defined by Cochrane (Stacey et al., 2017) as “interventions 
designed to support patients’ decision-making by making explicit the decision, providing 
information about treatment or screening options and their associated outcome.”  
Prior publications have focused on the impact of timing of the decision as related to 
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mammography screening participation. The use of DAs in preference-sensitive BCS decision-
making by adult women has been examined by randomized control trials (Bourmaud et al., 2016; 
Schapira et al., 2016; Hersch et al., 2015; Mathieu et al., 2010). These trials all provided a DA to 
women outside of an encounter with a health care provider in the community setting. Written 
material and/or a web link for an online DA was sent by mail directly to the home of the women 
registered with the government for nationalized healthcare services outside of the US as was 
accomplished in this MPD project.  Prior trials demonstrate that women who utilized a DA in the 
community setting are more likely to either seek and obtain mammography screening sooner 
than their control counterparts, or defer screening mammography, based on individual values and 
preferences (Bourmaud et al., 2016; Hersch et al., 2015; Mathieu et al., 2010). This preference 
and value-based expression of decision-making aligns with the mandate from within the US 
healthcare system imposed by ACOG (2016). 
Cost-Benefit analysis (Table 2) revealed project benefits and as such the project 
commence with support from Dr. Gene Harkless, Chair, Department of Nursing, University of 
New Hampshire.  
Table 2.  Cost-Benefit Comparison 
Strengths 
*Transparent process with clear goals 
*Informative communication to community 
*Paperless (web-based) interactive process 
*Empowerment of individualized decision-making 
based on values and preferences 
*Reduction in unnecessary screening 
*More effective appropriation of healthcare funds 
related to mammography overuse 




*Time consuming process for unique evidence-based 




*Enhancement of individualized BCS decision-making 
based on values and preferences 
*Service to UNH community 
*Improvement in maturity of UNH organizational 






*Resistance to apply unique DA to other topics due to 
time consuming DA development process (desire to 
implement pre-existing educational material provided 
by insurer) 
*Stakeholders (UNH community, UNH HR, corporate 




The purpose of this quality improvement project was to pilot a clinical practice DA to 
provided evidence-based information about the harms and benefits of BCS directly to a 
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convenience sample of women at average risk for breast cancer between the ages of 40 and 69 in 
the community setting. The specific aim of this project is to enhance preparedness for decision-
making through provision of a DA that is perceived as helpful to the user. This evidence 
translation project first developed a DA resource for practice called “My Personal Decision” 
(MPD) based on systematic review as presented in an educational leaflet. This leaflet titled: 
“Screening for breast cancer with mammography” (Gøtzsche et al., 2012), was published by the 
Nordic Cochrane Center and used with permission from primary author Dr. Peter Gøtzsche. The 
presentation was evaluated by community participants for alignment with personal value and 
preference-based educational needs, usefulness and influence on personal beliefs about BCS. 
This presentation was not for women who have a personal history of breast cancer or family 
history of breast cancer in a first-degree relative (such as a mother or sister) or other factors that 




 A convenience sample of women in the general community setting was solicited through 
social media and email invitation by other community women. Minimal restrictions were 
imposed on participants beyond request for women between the ages of 40 and 69, who are not 
known to be at high risk (thus by default average risk) for breast cancer. A general community 
sample was deemed advantageous for its relatively heterogeneous composition across 
educational preparations, socioeconomic backgrounds, cultural expectations and religious 
preferences.   
 
Intervention 
 There were two components of the intervention. First, the presentation was compiled 
from systematic review and based on the publication leaflet “Screening for breast cancer with 
mammography” as published by the Nordic Cochrane Center (Gøtzsche et al., 2012). This DA 
was chosen as foundation for this project based on its formation from systematic review as well 
as its ability to inform individualized value and preference-based BCS decision-making in 
accordance with International Patient Decision Aid Standards (Elwyn et al., 2006).  
16 
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The educational leaflet “Screening for breast cancer with mammography” was initially 
developed in 2008 by Dr Peter Gøtzsche for distribution to women through the National Board 
of Health in Denmark (Gøtzsche et al., 2012). Development of the leaflet was driven by concerns 
about misrepresentation of the benefits of BCS in similar educational leaflets in the United 
Kingdom. Primary author Gøtzsche states that materials in prior leaflets were “insufficient, one-
sided and erroneous” in their actual risk representations. In 2012 the leaflet was updated and 
republished with the opening statement acknowledging recent improvement in early treatment of 
breast cancer. This advance in treatment has led to the observation in randomized controlled 
trials that mammography screening is no longer beneficial in significant reduction of risk of 
dying from breast cancer (Gøtzsche et al., 2012). This leaflet has subsequently been favorably 
evaluated by multiple authors (Gummersbach et al., 2015; Henriksen et al., 2015; vanAgt et al., 
2014). The content of the leaflet was extracted as guided by Elkin et al., (2017), Saver et al. 
(2017), Yi et al. (2015), Stacey et al. (2014), and outlined in Microsoft® PowerPoint 
presentation with corresponding narrative script. Actual risk content was portrayed in “theater 
images” as described in Rifkin & Lazris (2015). The title MPD was adopted and the presentation 
was recorded for video presentation.  
 The second component of the intervention was provision of MPD to the community. As 
previously stated, the DA, MPD was trialed in the community setting with a convenience sample 
of women ages 40-69. The convenience sample was solicited through social media contact 
facilitated by the author and through notification via newsletter by the HealthyUNH program. No 
attempt to control participant attributes was made beyond pre-test questions that identify 
participant age and risk status for breast cancer. A link to the online presentation MPD in 
narrated video format included the pre- and post-evaluation usefulness, integrity of value and 
preference-based decision-making it produces as well as impact on decision intent and decisional 
conflict experienced by users. The presentation was available for a period of 2 weeks with a 
convenience sample of 66 participants at the time of review of the evaluation data.   
Collaboration with faculty mentor Dr. Gene Harkless was undertaken at each step in the 
intervention plan process for MPD. Permission for use of the leaflet “Screening for breast cancer 
with mammography” and its contents was provided by Dr. Peter Gøtzsche by email, and the 
source was cited within the presentation and in all supporting documents. The project was 
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support by the HealthyUNH program for personal and professional development purposes. 
However, no financial support was provided by HealthyUNH or any other outside source.  
 
Study of the Intervention 
 Qualtrics survey software was utilized to present and collect quantitative data 
immediately prior to and after presentation of MPD. This concise (14 question total) pre- and 
post-evaluation tool was developed based on the expectancy value theory as described by Eccles 
(1983) in which expectancies for success, and subjective task values are noted to determine the 
experienced value of an educational activity. The pre-post evaluation instrument is provided in 
Appendix A. Data was collected at the point of entry to the MPD link by question and response 
in the Qualtrics software.  
 
Measures 
Pre- and post-evaluation/test data was exported and analyzed in JMP software (SAS, 
2017) to validate individual reliability of understanding of the questions by mosaic plot, and to 
determine knowledge shift by development of 5 by 5 contingency table with subsequent 
evaluation of Fisher’s Exact Test and Bowker’s test. Generation of understanding of the value 
and utility of the presentation as well as the impact of MPD on the screening decision was 
evaluated through observation of numeric results and review and categorization of presentation 
comments.   
Weekly review of data for observation of comments and suggestions as well as overt 
patterns of response was completed by this student and faculty advisor. This continued until 4-8-
18 when formal data analysis commenced as described above. Subtle changes were made based 
on feedback from participants and are noted in the timeline within Table 3. Monetary and 
emotional costs were not noted through that process. After data collection, the decision was 
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Table 3.  
Evolution of project: Timeline 
 
Goals Objectives Expected Outcomes 
1. This student will identify 
valid evidence-based DA about 
BCS and created unique 
presentation called MPD to 
convenience sample of women 
ages 40-69 in community 
setting.  
1. To adopt valid, objective, evidence-
based DA for presentation and use in 
BCS decision-making by women ages 
40-69 for improvement of 
individualized value and preference-
based decision-making.  
1. Adoption of DA and creation of 
presentation as described.  
Initial Goal date: 10/1/17 
Delay attributed to unexpected modifications, need to receive training and IT support for enhanced functionality 
of Qualtrics platform. Additional goal added to obtain permission and support from Nordic Cochrane Center. 
Actual date: 12/14/17 
2. This student will disseminate 
MPD by email invitation with 
link to web-based tool that will 
evaluate pre- and post-intent for 
screening and decisional conflict 
with post value/utility as a DA. 
2. To swiftly and effectively 
disseminate MPD to small convenience 
sample that is easy to use and increases 
likelihood of individual participation. 
2. Effective and efficient 
solicitation of participation that 
encourages/supports small 
convenience sample of 75-100 
participants. 
Initial goal date: 10/30/17 
Delay attributed to delay in presentation finalization as well as holiday (5 week) break that separated faculty and 
student from ability for ongoing consultation. HealthyUNH dissemination was paused mid-February due to 
concerns about potential perception of provision of financial support by community members. The eventual 
decision to pursue distribution individually through social media contact was made and performed on 2/27/18. 
After initial posting and 6 participants, it was noted that it was possible to separate instructions and presentation 
link. Thus, instructions were moved from social media posting to inclusion as item #1 in Qualtrics survey. 
Reference list was initially included in the video presentation but was replicated, based on feedback, in the 
conclusion (thank you page) of the Qualtrics survey after 20 participants were recorded.  HealthyUNH 
dissemination of presentation link was pending at the time of this report.   
Actual date: 2/27/18 
3. This student will analyze data 
for impact on preparation for 
decision-making about BCS, 
perceived usefulness of MPD. 
3. To identify the usefulness of MPD as 
related to impact on preparation for 
decision-making about BCS and 
perceived overall usefulness of MPD. 
 
 
3. Descriptive and statistical data 
that enunciate the perceived 
usefulness of this type of DA and 
impact on preparation for decision-
making that can be replicated and 
or utilized in future practice 
changes. 
Initial goal date: 2/28/18 
Delay due to prior delays.  
Actual data: 4/1/18 
4. This student will report 
finding results in visual and 
written format. 
4. To present findings in effective 
manner that verifies completion of 
requirements of DNP project and 
outlines practice changes that can be 
implemented in future practice settings.  
 
4. Well received presentation of 
results in visual and written format 
that are considered for publication. 
Initial goal date: 4/30/18 
Actual date: 4/30/18 
Initial goal date: 9/1/18 
Revised goal date: 6/30/18 
 
Completeness and accuracy of data was assessed through review of the recorded data and 
pattern of missing data evaluation. 66 people were noted to participate in the presentation. It was 
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noted that the post-evaluation results for only 42 people were documented in Qualtrics®. Upon 
consultation with Dr. Phil Ramsey, he stated “that the statistical probability that this pattern of 
data omission occurred randomly is nil” It was postulated by Dr. Ramsey that a technical error in 
Qualtrics® was more likely than a lack of participant response to cause this type of omission.  
However, most participants a positive response to the usefulness of the tool and assistance with 
decision-making in the form of supportive comments and or neutral observations (Table 4) was 
noted.  Therefore, evaluation of the response data commenced as planned based on 42 completed 
responses. 
Table 4. #18. “As this project aims to improve the provision of evidence-based 
information to the community, please feel free to share any additional comments and or 
suggestions in the space below. Thank you!” 
 
Supportive comments ✓ I wish I could see the video again- there is a lot of information there I wish I wrote some 
things down. 
✓ At my age I think it's hard to be critical of my younger self who followed my providers 
advice and got mammograms from age 40- on. Now, I am frustrated about all that wasted 
time and energy. I had to have follow up testing twice and it was awful! Painful and 
stressful! It made me scared every time I have one. I wish someone had told me this 20 
years ago. 
✓ Too short! I want to know more!! I feel like the media is distracting us! 
✓ Great presentation! I liked Wildcat stadium! 
✓ This is shocking! Crazy! I am going to email Kim and ask for more info!!! 
✓ I think it would be great to include the ability to stop/rewind during the video. Also 
sharing the length of the video would be great. I had a phone call in the middle and missed 
some but I was able to watch and think I didn't miss much. Thanks for a great video! 
Neutral comments/ 
observations 
➢ Questions11,15,16 I answered, "no opinion" but actually would have said, "confused" 
with the reason being that I have always been told that the mammography was the best 
available test to detect breast cancer. It is hard to get away from that thought process! 
➢ This is similar to the debate on PSA tests for men.  
➢ It would be nice to know the alternatives to mammography. 
➢ It was difficult to answer the benefits and harms questions accurately because the 
presentation shows that there is a benefit to mammography at greater than 50 years. 
Though it's not something that has to be done yearly, screening should be done at some 
intervals. I did not believe in yearly screening for someone of average risk before or after 
the presentation, however I was made more aware of the negative effects of 
mammography 
➢ I would have liked to be able to read all of the text. 
➢ Language used not appropriate for all patients. I would aim to have the language at a 
grade 8 level at most. Have fewer talking points and have text to go with all spoken 
words. Would also suggest including links where people can go for more info. 
➢ The presentation seemed biased against mammogram screening-although I thought your 
data was fair and what I have heard previously in studies. 
➢ This was very interesting but I'd like to do some fact checking about the risks of 
mammography. 
➢ What about 3d mammography? 
Negative comments/ 
Critical observations 
▪ I feel like this presentation overemphasizes a lot of the "harm" caused by screening. I can't 
help but shrug off a lot of the "facts" it presents due to its biased assumptions - e.g., that 
every false positive is stressful to the patient, or that the harm of being stressed is 
somehow as important as the benefit of receiving timely cancer treatment.  
▪ I would hate for this presentation to scare women off from having a mammogram just 
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Analysis 
Two similar questions were asked prior to the presentation: “#4. There are more benefits than 
harms related to breast cancer screening (mammography)” and “#5. There are more harms than 
benefits related to breast cancer screening (mammography).” The purpose of the questions was 
to establish that respondents understood the questions being asked and establish belief in regard 
to the concepts of harm and benefits related to BCS.  The responses were examined for inverse 
relationship in order to reflect participant understanding of the questions and corresponding 
consistency in response.  
Contingency Tables were generated, Fisher’s Exact Test results observed for Probability > 
Chi-squared which provides the probability that chance alone can produce a Chi-squared value 
greater than the calculated value in the absence of a relationship between the variables. 
Subsequently, Bowker’s test was applied to the matched set of pre- and post-evaluation questions 
for symmetry of disagreement thus reflecting change in knowledge and opinion before and after 
MPD. 
The final step in analysis was report of actual results of post-evaluation questions that 
provided feedback about usefulness and helpfulness of the presentation. Categorization of 
feedback comments as supportive, neutral and negative/critical provided anecdotal observations 
and suggestions for future improvement and are presented in Table 4 as previously reported. 
 
Ethical Considerations 
UNH Internal Review Board (IRB) approval is not necessary due to the quality 
improvement intent for this project. However, ethical consideration related to the collection of 
data includes adherence to Health Insurance Portability and Accountability Act of 1996 (HIPPA) 
to protect the privacy of individual patient information. For both community members and 
employees of UNH, the protection of privacy of electronic communication in the completion of 
the pre- and post-test questionnaires as mandated by the Electronic Communications Privacy Act 
of 1986 (ECPA) (Federal Privacy Council, 2016) is acknowledged and guided the further 
protection of privacy of data collected. No identified list of participants was collected and only 
ISP identifiers were gathered by Qualtrics. This was separated from data prior to aggregation. All 
electronic files that contain ISP information (prior to de-identification and aggregation) are 
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password protected and isolated from unauthorized use by people other than this student and the 
faculty mentor. No further identifiable information was collected. 
 Further ethical consideration related to the impact of the information provided was 
considered in the context of empowerment of individualized decision-making with 
acknowledgment about the harms and benefits of BCS. As such, voluntary participation was 
solicited and the MPD presentation included only evidence-based presentation of these harms 
and benefits as established by Gøtzsche & Jorgensen (2013), Hersch et al. (2015), Jorgensen et 
al. (2017) Loberg et al. (2015), Pace & Keating (2014) and Welch et al. (2016). This information 
is acknowledged to be contrary to popular media campaigns that advocate for mammography 
screening at ages prior to those noted to be beneficial through evidence-based research. 
Additionally, it is acknowledged that the harms of mammography, particularly overdiagnosis and 
overtreatment, are under acknowledged in professional recommendations as well as in the public 
media, and may be surprising and concerning to some participants (Gøtzsche, 2015). In 
recognition of this, a complete description of the intent of the project as quality improvement and 
basis on well-established evidence-based research was provided prior to the content of MPD. 
Additionally, the choice of a tool that was based on systematic review and validated through 
previous study was made to reduce the risk of conflict related to a potentially invalidated tool. 
Contact information for the student presenter was provided at the beginning of the program as 
well as in the introduction provided on the initial social media post.  
 
Results 
The initial steps of the MPD intervention process and the evolution over time are reported 
in Table 3. Minor modifications were made to the intervention presentation in Qualtrics® during 
the project and are reported in Table 3. No changes to the video presentation, questions or 
content were made after initial dissemination. As previously stated, pre- and post-evaluation data 
was exported from Qualtrics® and analyzed in JMP software (SAS, 2017). JMP labeled results 
with warning “Warning: 20% of cells have expected count less than 5. ChiSquare is suspect. 
Warning: Average cell count less than 5, LR ChiSquare suspect.” This warning is elicited by the 
small sample size. Although while results are not noted to demonstrate a true difference for this 
small sample size, findings are noted to be informative about the understanding and change in 
belief before and after presentation as follows. 
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Initially, it was important to note that there is an inverse relationship between the two 
similar questions: “#4. There are more benefits than harms related to breast cancer screening 
(mammography)” and “#5. There are more harms than benefits related to breast cancer screening 
(mammography).” (Table 5), thus validating a pattern of consistency in response. The likelihood 
that the difference is from chance is less than 0.01% (p<.0001). Based on the observation that 
participants understood the questions, subsequent analysis proceeded.  
 
Table 5. “There are more benefits than harms related to breast 
cancer screening (mammography)” BY “There are more harms than 










































































 48.724 <.0001 
Warning: 20% of cells have expected count 
less than 5. ChiSquare is suspect. 
Warning: Average cell count less than 5, 













 42.45833 <.0001 
Only 4 levels that agreed occurred. 
 
Bowker’s test for symmetry of disagreement was applied to the pre- and post-questions to 
determine if opinion about benefits and harms changed post presentation. A change was noted, 
from pretest to posttest, in opinion for the question: “There are more benefits than harms related 
to breast cancer screening (mammography)” (Table 6). In actual terms, 36 participants 
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agreed/strongly agreed to the statement before the presentation, while 19 people agreed/strongly 
agreed after the presentation. The Fisher’s Exact Test confirmed the presence of the findings as 
noted in Table 6.  
 
Table 6. “There are more benefits than harms related to breast 
cancer screening (mammography).” Pre-by-Post 
Contingency Table 
Count 












































































 22.335 <.0001 
Warning: 20% of cells have expected count 
less than 5. ChiSquare is suspect. 
Warning: Average cell count less than 5, 












 21.29 0.0192 
Only 4 levels that agreed occurred. 
 
Further, 14 out of 34 participants changed response from disagreement that harms 
outweigh benefits toward agreement that harms outweigh the benefits of BCS (Table 7). Only 1 
participant agreed/strongly agreed there are more harms than benefits prior to the presentation 
and 20 agree strongly agree responses were recorded in post-evaluation to the same statement. 
Six out of seven people who declared no opinion to the statement that harms outweigh the 
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Table 7. “There are more harms than benefits related to breast 
cancer screening (mammography).” Pre-by-Post 
Contingency Table 
Count 














































































 14.404 0.2757 
Warning: 20% of cells have expected 
count less than 5. ChiSquare is suspect. 
Warning: Average cell count less than 5, 












 22.33 0.0135 
 
A small, not statistically significant knowledge shift was reflected by the question: 
“There is a risk of being told I have a tumor on my mammogram that requires further testing 
when there is no concern or harmful growth present” (Table 8). 31 of 42 participants responded 
agree/strongly agree to this statement prior to the presentation and 38 responded agree/strongly 
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Table 8. “There is a risk of being told I have a tumor on my 
mammogram that requires further testing when there is no concern 
or harmful growth present.” Pre-by-Post 
Contingency Table 
Count 














































































 23.277 0.1065 
Warning: 20% of cells have expected 
count less than 5. ChiSquare is suspect. 
Warning: Average cell count less than 5, 













 6.87 0.7380 
 
For the question: “There is a risk of being told I have breast cancer and receiving 
treatment when there is no concern or harmful growth present,” Bowker’s test demonstrates 
(Table 9) there are only slightly significant differences in pre- and post-response. Seven people 
changed their response from disagree to agree post evaluation (25 disagree/strongly disagree pre-
test and 32 agree/strongly agree post-test). Further, 11 people who reflected no opinion prior to 
the educational intervention agreed there is a risk of receiving treatment when there is no 
concern about breast cancer after viewing the DA. This non-significant but informative change 
may reflect the need for enhancement of the definition of the concepts “treatment” and/or  
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Table 9. “There is a risk of being told I have breast cancer and 


















































































  0.1169 
Warning: 20% of cells have expected 
count less than 5. ChiSquare is suspect. 
Warning: Average cell count less than 5, 













 26.25 0.0034 
 
Generation of understanding of the value and utility of the presentation, and the impact of 
MPD on the screening decision were evaluated through evaluation of actual results for the 
questions: # 15 (Table 10) and #16 (Table 11). Most participants (80.94%) reported they agree or 
strongly agree with the statement: “#15. This presentation helped me to make an informed 
decision about breast cancer screening” (Table 10).  
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Thirty-five (83.34%) of 42 respondents reported they agree and or strongly agree with the 
statement “#16. After watching this presentation, I feel better prepared to make a decision about 
breast cancer screening.” (Table 11).  
Table 11. 
“#16. After watching this presentation, I 
feel better prepared to make a decision 
about breast cancer screening.” 
Level of Agreement             n (% total)  
Strongly Agree  16 (38.10%)  
Agree 19 (45.24%) 
Strongly Agree & Agree 35 (83.34%) 
No Opinion 4 (9.52%) 
Disagree 3 (7.14%) 
Strongly Disagree 0 (0%) 
Total  42 
 
Participants were invited to choose as many responses as apply to the question: “#17. I 
found this presentation to be (choose ALL that apply)” (Table 12). 34 of 42 participants found 
the presentation to be “understandable”. 32 participants reported the presentation was “helpful” 
to decision-making and 27 chose the descriptor “interesting.” Finally, 23 reported that the 
presentation was “reasonable length.” This was the outcome expected by the student author as it 
is consistent with prior publication and observations.  
  
Table 10.  
“#15 - This presentation helped me to 
make an informed decision about breast 
cancer screening.” 
Level of Agreement n (% total) 
Strongly Agree  15 (35.71%) 
Agree 19 (45.24%)  
Strongly Agree & Agree 34 (80.95%) 
No Opinion 5 (11.9%) 
Disagree 3 (7.14%) 
Strongly Disagree 0 (0%) 
Total  42 
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Table 12. 
“#17. I found this presentation to 
be (choose as many as apply):” 
Response                                n 
Understandable  34 
Helpful 32  
Interesting 27  
Reasonable length 23  
Too long 6  
Too short 2  
Too complicated for me 1  
Not Helpful 1  
Confusing  0  
 
Review and categorization of presentation comments (Table 4) reflects that generally 
neutral observations were noted by participants. Most comments were observational about the 
impact of the information and its inconsistency with many commercial media presentations. The 
majority of comments (total = 9) such as “I would like to do some fact checking” were 
determined to be neutral as the content of the presentation was evidence-based and well 
referenced within the presentation and post evaluation context in Qualtrics®. Supportive 
comments (total =6) were emotive and expressive. Comments such as: “Great video!” and “I 
wish I could see the video again” were noted. Critical comments (total = 2) reflected a lack of 
appreciation and or understanding of the content as derived from systematic review.  
Over the course of initial dissemination of this project, 66 responses were recorded. Of 
the 66 participants, 42 completed both the pre- and post-evaluation questions provided in the 
survey. Only the completed, paired responses were evaluated in analysis. Contextual elements 
that interacted with the MPD presentation are presumed to be individual comfort and skill with 
the online platform and technology, prior knowledge related to the benefits and harms of BCS as 
well as prior belief structures based on commercially based social and political campaigns. 
While, comments do not reveal criticism with the technological platform, the fact that 24 
participants did not progress to the post-evaluation questions causes the need to consider 




BREAST CANCER SCREENING DECISION AID 
Discussion 
Summary 
Analysis of the pre- and post-evaluation responses revealed that people understood the 
questions asked and the presentation changed their opinion about the harms and benefits of BCS. 
Further participants reflected enhanced preparedness for informed decision-making about BCS. 
The aim of the project was to pilot a clinical practice DA to provide evidence-based information 
about the harms and benefits of BCS. The results of data analysis demonstrate differences in pre-
and post-test evaluation that highlight the value of provision of high-quality information in an 
understandable format to support women’s personal preference-based decision-making about 
participation in BCS. It must be noted that the results of data analysis were not statistically 
significant due to the small sample size. However, the findings are informative about the value of 
an evidence-based DA in enhancement of preparedness for BCS decision-making. Further, the 
results provide initial feedback for improvement of the presentation and format. It is apparent 
that some questions contain concepts that may need to be defined further such as “harm” and 
“harmful growth.” The definition of these concepts can be included in the instructional material 
and further evaluated by the pre- and posttest. Additionally, the language level of the 
presentation should be assessed for opportunities to reduce the literacy level to grade 7 or 8. 
Alteration of the presentation content for literacy level of grade 7 or 8 would be helpful in 
subsequent presentation to enhance the understanding of a broader audience.  
 The strengths of this project include the accessibility provided by the Qualtrics format as 
well as visual and written presentation of evidence-based information that was previously 
implemented and validated by the Nordic Cochrane Center among others. The visual and 
auditory presentation meets the needs of both visual and auditory learners. Use of online format 
has been demonstrated to improve accessibility to a larger audience of learners than written, 
mailed format utilized by Gøtzsche et al. (2012). Ultimately, the support of value and preference-




The impact of the MPD project on people and systems can be reflected in question #16. 
“After watching this presentation, I feel better prepared to make a decision about breast cancer 
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screening.” (Table 10). Most participants reported enhanced preparedness for decision-making 
because of this presentation. A change in opinion was noted related to the question: “There is a 
risk of being told I have breast cancer and receiving treatment when there is no concern or 
harmful growth present.” This demonstrates a shift in belief structure that was informed by the 
presentation. The reality that treatment is provided to women who do not have breast cancer was 
clearly previously not opined by participants. Further, most women reported MPD was 
understandable, helpful, interesting and reasonable length.   
The previously established role of an evidence-based DA in support of value and 
preference-based decision-making is consistent with the findings of this project. The individual 
value of MPD, change in opinion based on exposure to the MPD presentation as well as 
corresponding helpfulness in decision-making, has been demonstrated. 
 
Limitations 
This quality improvement project had several limitations in implementation. The small 
sample size achieved prior to the need for results analysis was unfortunate as responses from 100 
or more women would have been preferred. Further, solicitation of the convenience sample via 
social media could have biased the participants toward support of the author/student. The 
participants’ desire to support the student/author’s efforts in completion of her education could 
influence the responses. The manner of this influence is unknown. Future measures could be 
implemented to control for awareness of the participant about the personal identity of the author 
of the presentation. However, this would remove the ability to provide contact in the event 
further comments and or support were desired by participants. Comments provided by 
participants in question “#18. As this project aims to improve the provision of evidence-based 
information to the community, please feel free to share any additional comments and or 
suggestions in the space below.” (Table 4) subjectively related the individual value of the 
observations by the participants and provide feedback about some of the concerns and or 
limitations as perceived by participants. 
Within hours of posting (after 6 participants had completed the presentation), an initial 
observation was made that the link to Qualtrics® could be separated from the posting in social 
media. This prompted relocation of the instructions to the first question of the Qualtrics® link. 
Therefore, the potential exists that the first 6 participants did not receive the same instruction as 
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the remaining participants. Further, the reference list was initially included in the video 
presentation but was replicated, based on feedback, in the conclusion (thank you page) of the 
Qualtrics® survey after 20 participants were recorded.  
Finally, the readability of the content factored by the Flesh-Kincaid tool at the 11th grade 
level and at similar levels with other tools (Gunning Fog; Coleman-Liau; Smog Index). This was 
partially attributed to the words overdiagnosis, overtreatment, evidence-based presentation, and 
examination. While these words were carefully defined within the presentation, their use could 
be re-evaluated and altered to reduce the readability of the dialogue to 7th-8th grade level in the 
future if desired. However, consideration would need to be provided for the variation in 
application from the original terms used in the Gøtzsche et al. (2012) leaflet on which MPD was 
based.  Generalizability of this project to other community settings is limited by the 11th grade 
readability level of the presentation. Consideration for implementation in other settings should 
consider adjustment of the readability to suit the educational level of the audience.  
As previously noted, post presentation responses were not recorded for 24 participants. 
Consideration of the potential of individual disinterest, technological challenges and or problems 
with the Qualtrics® platform and potential loss of data must be investigated before use of this 
platform in the future. At the date of publication of this report, no explanation for the missing 
data was available beyond the presumption that individual participants voluntarily provided pre-
evaluation responses but closed out of the presentation at some point prior the completion of the 
video and post-evaluation questions. The impact of this limitation resulted in a smaller than 
desired sample size and should be addressed in future iterations of the project to prevent loss of 
evaluation data.  
The HealthyUNH pause in dissemination, due to concerns expressed about potential 
perception of financial support, contributed to reduction in participant responses available at the 
time of data assimilation. Due to the timeline imposed by DNP studies, data analysis was 
initiated on 4-1-18. However, the perceived value of the tool by HealthyUNH and the UNH 
community was determined and dissemination was continued as planned and started after 
compilation of this report on 4-8-18.  
One entry from the initial reported as posted on 4-8-18 was deleted due to comment in 
the final note field that stated: “testing only- remove this entry- it can’t count in your data.” 
Consult with faculty agreed that this was likely the response of another department faculty 
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member who performed an unsolicited “test” of the survey. One benefit of use of the Qualtrics 
platform is the ability to force response to each question before progressing through the 
presentation. Superficially, this is helpful to information gathering. However, the chance that an 
undesired answer is provided to progress the presentation must be acknowledged. No further 
missing data or data requiring elimination was noted. 
 
Conclusions 
Overall, this project demonstrates that providing evidence-based information directly to 
women outside of a clinical consultation may be acceptable, informative, and perceived as 
valuable in the BCS decision-making process.  These findings are important as understanding of 
evidence-based information is a fundamental element in the empowerment of the decision maker 
with the goal of informed decision-making. 
Evaluation feedback from the participants before and after use of the tool demonstrated 
that MPD was helpful and enhanced preparedness for BCS decision-making.  
The usefulness of the MPD tool can be incorporated into the SDM process in the clinical setting. 
However, it has demonstrated utility as a tool for individual use outside of the clinical encounter.  
The HealthyUNH program is committed to enhancing the use of shared decision-making across 
many healthcare decisions for the community at UNH.  Projects like this one, that provide 
evidence-based information directly to community members about a healthcare decision, can be 
provided to improve the content of evidence-based information available in the community, and 
support individual informed (and shared) decision-making across many healthcare decisions.  
This presentation will be sustained by the HealthyUNH program for the upcoming 3-4 months. 
The Qualtrics link will continue to be sponsored by the HealthyUNH program staff with access 
to the MPD presentation and pre- and post-presentation questions. Ongoing evaluation of the 
appropriateness of continuation of the MPD presentation and potential revisions will be at the 
discretion of the HealthyUNH program.  
The implications for practice and for further study include the utilization of similar 
evidence-based presentations to the community about screening decisions beyond BCS. These 
may include evidence about screening for prostate cancer with prostate-specific antigen (PSA) 
and/or for cervical cancer with Papanicolaou (Pap) and human papillomavirus (HPV) testing 
among others. Based on the recognition that screening tests have harms as well as benefits, the 
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USPSTF has taken initiative to advocate for the use of informed and shared decision-making for 
support of screening decisions. Presentations such as MPD serve to disseminate accurate, 
evidence-based information to support value and preference-based decisions across these topics 
as identified by the USPSTF. Adoption of evidence-based presentations that educate the decision 
maker about the harms and benefits in actual risk terms would assist the empowerment of the 
individual towards more individualized screening decision-making. Through performance of 
value and preference-based decisions, the individual is able to comprehend and integrate the 
consequences of the decision and choose actions consistent with discrete values and preferences. 
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Appendix 
Appendix A: Presentation format with pre and post evaluation questions by number as 
presented in Qualtrics® UNH. 
____________________________________________________________________________ 
1. Welcome! 
I am asking women between 40 and 69, at average risk for breast cancer, to participate in this quality improvement project that 
seeks feedback on an evidence-based educational program about breast cancer screening.   
  
 This project asks you to answer a few short questions, watch an evidence-based presentation about the benefits and harms of 
breast cancer screening, and provide me feedback about your experience.  
 
 Estimated total time to completion about 12 minutes 
The presentation link is confidential and does not track identifying user information. 
 
Thank you! 
Kimberly C. Gibbons, MS, RN, CNM, CNL 
Doctor of Nursing Practice Student 
University of New Hampshire 
Kimberly.gibbons@unh.edu 
  
*Based on: Gøtzsche, P.C., & Jørgensen, K.J. (2013). Screening for breast cancer with mammography. Cochrane Database 
of Systematic Reviews, 6(CD001877). DOI: 10.1002/14651858.CD001877.pub5. 
Full reference list available upon request from Kimberly.gibbons@unh.edu 
_________________________________________________________________________________________________________ 
2. How old are you? Please type in your age. This is confidential. ______ 
 
3. I know that I am at higher risk for developing breast cancer. I have been diagnosed with breast cancer and or I have a first-degree 
relative with breast cancer (mother or sister) and or I know I have genetic or other factors that put me at high risk for development of 
breast cancer.  
True - False 
 
4. There are more benefits than harms related to breast cancer screening (mammography). 
Strongly Agree – Agree - No opinion – Disagree - Strongly Disagree 
 
5. There are more harms than benefits related to breast cancer screening (mammography). 
Strongly Agree – Agree - No opinion – Disagree - Strongly Disagree 
 
6. There is a risk of being told I have a tumor on my mammogram that requires further testing when there is no concern or harmful 
growth present. 
Strongly Agree – Agree - No opinion – Disagree - Strongly Disagree 
 
7. There is a risk of being told I have breast cancer and receiving treatment when there is no concern or harmful growth present. 
Strongly Agree – Agree - No opinion – Disagree - Strongly Disagree 
 
8. The best age to begin to have annual (every year) mammograms is:  
35 – 40 – 45 – 50 – 55 – 60 – 65 - Never 
_________________________________________________________________________________________________________ 
9. <<PRESENTATION>> 
Link available: https://www.youtube.com/edit?o=U&video_id=ADF54UNurLA  
_________________________________________________________________________________________________________ 
10. <This question records and manages how long a participant spends on this page. This question is not displayed to the 
participant.> 
 
11. There are more benefits than harms related to breast cancer screening (mammography). 
Strongly Agree – Agree - No opinion – Disagree - Strongly Disagree 
 
12. There are more harms than benefits related to breast cancer screening (mammography). 
Strongly Agree – Agree - No opinion – Disagree - Strongly Disagree 
 
13. There is a risk of being told I have a tumor on my mammogram that requires further testing when there is no concern or harmful 
growth present. 
Strongly Agree – Agree - No opinion – Disagree - Strongly Disagree 
 
14. There is a risk of being told I have breast cancer and receiving treatment when there is no concern or harmful growth present. 
Strongly Agree – Agree - No opinion – Disagree - Strongly Disagree 
 
15. This presentation helped me to make an informed decision about breast cancer screening. 
Strongly Agree – Agree - No opinion – Disagree - Strongly Disagree 
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16. After watching this presentation, I feel better prepared to make a decision about breast cancer screening. 
Strongly Agree – Agree - No opinion – Disagree - Strongly Disagree 
 
17. I found this presentation to be (choose ALL that apply): 
Understandable 
Too complicated for me 
Reasonable length 
Too long 






18. As this project aims to improve the provision of evidence-based information to the community, please feel free to share any 
additional comments and or suggestions in the space below. Thank you! ______________ (free text response)______________ 
_________________________________________________________________________________________________________ 
19. Thank you!  
Your input is appreciated and we hope you are better prepared to move forward with  
Your Personal Decision! 
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